Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Share Price
NASDAQ: KNSA | Mid CapKiniksa Pharmaceuticals International, plc Class A Ordinary Shares Stock Performance
Open $76.40 | Prev. Close $76.63 | Circuit Range N/A |
Day Range $75.71 - $76.43 | Year Range $31.80 - $82.65 | Volume 5,458 |
Average Traded $75.95 |
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Share Price Today
As of 8 August 2026, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's share price is $75.77. The stock opened at $76.40, compared to its previous close of $76.63. During today's trading session, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's share price traded between $75.71 and $76.43, with an average price of $76.07. Over the past 52 weeks, the stock has recorded a high of $82.65 and a low of $31.80. In terms of performance, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's share price has risen by 70.25% over the last six months and is up 126.31% on a year-on-year basis.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Share Price Chart
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Stock Fundamentals & Key Indicators
Market Cap $5.62B | PE Ratio (TTM) 94.71 | Dividend Yield N/A |
EPS (TTM) $0.80 | Revenue (TTM) $677.56M | Return On Equity (TTM) 10.40% |
Profit Margin 8.71% | Debt to Equity 0.25 | Quarterly Earnings Growth YoY 245.24% |
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Quarterly Profit & Loss
All figures in USD
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Annual Profit & Loss
All figures in USD
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $73.19 | $75.81 | +1.90% |
Jul 2026 | $63.51 | $74.40 | +16.40% |
Jun 2026 | $47.66 | $63.92 | +32.09% |
May 2026 | $53.38 | $48.39 | -9.96% |
Apr 2026 | $48.90 | $53.74 | +11.29% |
Mar 2026 | $44.13 | $48.29 | +8.50% |
Feb 2026 | $43.84 | $44.51 | +1.40% |
Jan 2026 | $41.50 | $43.89 | +6.58% |
Dec 2025 | $42.39 | $41.18 | -3.08% |
Nov 2025 | $37.48 | $42.49 | +14.96% |
Oct 2025 | $38.78 | $36.96 | -4.91% |
Sep 2025 | $33.66 | $38.87 | +16.10% |
KNSA Share Price FAQs
What is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares share price today?
What is the 52 week high and 52 week low of Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares stock?
What is KNSA's market capitalisation today?
What is KNSA's net income for the last quarter?
What is the 5 year returns of KNSA?
What is the high & low stock price of KNSA today?
Can I buy KNSA shares in India?